Cargando…

Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective

Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liang, Wang, Qiong, Zhang, Yan, Liang, Jingqi, Liu, Peilong, Zhao, Hongmou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130761/
https://www.ncbi.nlm.nih.gov/pubmed/37124200
http://dx.doi.org/10.3389/fphar.2023.1160278
_version_ 1785031027722289152
author Liu, Liang
Wang, Qiong
Zhang, Yan
Liang, Jingqi
Liu, Peilong
Zhao, Hongmou
author_facet Liu, Liang
Wang, Qiong
Zhang, Yan
Liang, Jingqi
Liu, Peilong
Zhao, Hongmou
author_sort Liu, Liang
collection PubMed
description Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN.
format Online
Article
Text
id pubmed-10130761
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101307612023-04-27 Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective Liu, Liang Wang, Qiong Zhang, Yan Liang, Jingqi Liu, Peilong Zhao, Hongmou Front Pharmacol Pharmacology Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN. Frontiers Media S.A. 2023-04-12 /pmc/articles/PMC10130761/ /pubmed/37124200 http://dx.doi.org/10.3389/fphar.2023.1160278 Text en Copyright © 2023 Liu, Wang, Zhang, Liang, Liu and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Liang
Wang, Qiong
Zhang, Yan
Liang, Jingqi
Liu, Peilong
Zhao, Hongmou
Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
title Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
title_full Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
title_fullStr Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
title_full_unstemmed Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
title_short Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
title_sort therapeutics of charcot neuroarthropathy and pharmacological mechanisms: a bone metabolism perspective
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130761/
https://www.ncbi.nlm.nih.gov/pubmed/37124200
http://dx.doi.org/10.3389/fphar.2023.1160278
work_keys_str_mv AT liuliang therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective
AT wangqiong therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective
AT zhangyan therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective
AT liangjingqi therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective
AT liupeilong therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective
AT zhaohongmou therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective